HOUSTON--(BUSINESS WIRE)--Dec. 14, 2015--
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage
biopharmaceutical company focused on discovering and developing novel
cellular immunotherapies for cancers and orphan inherited blood
disorders, today announced that the Company has been selected for
inclusion in the NASDAQ Biotechnology Index® (Nasdaq: NBI).
This addition will be effective prior to market open on Monday, December
The NASDAQ Biotechnology Index is designed to track the performance of a
set of securities listed on The NASDAQ Stock Market® (NASDAQ®)
that are classified as either biotechnology or pharmaceutical according
to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology
Index is calculated under a modified capitalization-weighted methodology
and ranked on an annual basis. All securities in the NASDAQ
Biotechnology Index are listed on the NASDAQ Global Market or the NASDAQ
Global Select Market, and meet minimum market value and share volume
requirements among other criteria. For more information about the NASDAQ
Biotechnology Index, including eligibility criteria, visit www.nasdaq.com.
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company focused on
discovering and developing cellular immunotherapies for cancers and
orphan inherited blood disorders. Bellicum is using its proprietary
Chemical Induction of Dimerization (CID) technology platform to engineer
and control components of the immune system. Bellicum is developing
next-generation product candidates in some of the most important areas
of cellular immunotherapy, including hematopoietic stem cell
transplantation (HSCT), and CAR-T and TCR cell therapies. More
information can be found at www.bellicum.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151214006297/en/
Source: Bellicum Pharmaceuticals, Inc.
Alan Musso, CFO,
Brad Miles, 646-513-3125